16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
514 694 0150
https://www.valeopharma.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 70
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Kyle Steiger | Senior VP & Chief Commercial Officer | 312k | N/A | N/A |
Mr. Al Moghaddam B. Com. Cma | Chief Executive Officer | N/A | N/A | 1967 |
Mr. Pascal Tougas | Chief Financial Officer | N/A | N/A | N/A |
Mr. Frederic Dumais | Director of Communications & Investor Relations | N/A | N/A | N/A |
Mr. Guy-Paul Allard | VP of Legal Affairs & Corporate Secretary | N/A | N/A | N/A |
Mr. Jean Francois Fournier | Head of Ophthalmology Business Unit | N/A | N/A | N/A |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.
Valeo Pharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.